drugset / Trial / NCT00864448

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT00864448

Phase 1 Completed 40 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated to healthy subjects after a 10-hour overnight fast

Timeline

Start
2004-10
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 10 mg Oral

Indications

No indication recorded.